RGNX Completes Dosing
REGENXBIO completes dosing in confirmatory study of RGX-202, marking completion of registrational development program and supporting planned BLA submission in Q3 2026
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.